Results 21 to 30 of about 46,296 (214)

LRRC8A promotes the initial development of oxaliplatin resistance in colon cancer cells

Heliyon, 2023
Leucine-rich repeat-containing 8 A (LRRC8A) is an essential component of the volume-regulated anion channel (VRAC), which plays a vital role in cell proliferation, migration, apoptosis, and drug resistance.
Haifeng Zhang, Zhenghui Jing, Rong Liu, Yassin Shada, Sindhwani Shria, Shiyu Cui, Yuhua Ren, Yuan Wei, Liangming Li, Shuang Peng   +9 more
doaj   +1 more source

WBSCR22 confers oxaliplatin resistance in human colorectal cancer [PDF]

Scientific Reports, 2017
AbstractHuman WBSCR22 gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of WBSCR22 was significantly elevated in human colorectal cancer (CRC) tissue. WBSCR22 could be served as an independent risk
Yan, Dongmei, Tu, Linglan, Yuan, Haining, Fang, Jianfei, Cheng, Liyan, Zheng, Xiaoliang, Wang, Xiaoju   +6 more
openaire   +2 more sources

The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer [PDF]

Frontiers in Molecular Biosciences, 2021
BackgroundColorectal cancer (CRC) is estimated to be one of the most common cancers and the leading cause of cancer-related death worldwide. SOX9 is commonly overexpressed in CRC and participates in drug resistance. In addition, DNA damage repair confers resistance to anticancer drugs.
Yiqiang Liu, Yiqiang Liu, Hong Wu, Tao Luo, Qiyu Luo, Ziyu Meng, Ying Shi, Feifei Li, Feifei Li, Mingxin Liu, Xinhao Peng, Junjie Liu, Chuan Xu, Weizhong Tang   +13 more
openaire   +3 more sources

Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer

Signal Transduction and Targeted Therapy, 2022
Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance.
Yimin Li, Yaqi Gan, Jiaxin Liu, Juanni Li, Zhengwei Zhou, Ruotong Tian, Ruizheng Sun, Jiaqi Liu, Qing Xiao, Yuanyuan Li, Pengyan Lu, Yulong Peng, Yuqian Peng, Guang Shu, Gang Yin   +14 more
doaj   +1 more source

NLRP3/IL‐1β induced myeloid‐derived suppressor cells recruitment and PD‐L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma

MedComm, 2023
Oxaliplatin is commonly used as the first‐line chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). Unfortunately, the acquired resistance, limits the effectiveness of oxaliplatin and the underlying mechanisms remain unknown. Therefore, we
Wenfeng Liu, Feng Zhang, Bing Quan, Fan Yao, Rongxin Chen, Zhenggang Ren, Xin Yin   +6 more
doaj   +1 more source

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer

Cancers, 2022
Resistance to treatments is one of the leading causes of cancer therapy failure. Oxaliplatin is a standard chemotherapy used to treat metastatic colorectal cancer. However, its efficacy is greatly reduced by the development of resistances. In a previous study, we deciphered the mechanisms leading to oxaliplatin resistance and highlighted the roles ...
Chocry, Mathieu, Leloup, Ludovic, Parat, Fabrice, Messé, Mélissa, Pagano, Alessandra, Kovacic, Hervé   +5 more
openaire   +2 more sources

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma

BMC Cancer, 2020
Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses.
Xia Liao, Ge Song, Zihan Xu, Yang Bu, Fan Chang, Fengan Jia, Xuelian Xiao, Xuejiao Ren, Mei Zhang, Qingan Jia   +9 more
doaj   +1 more source

MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer

Frontiers in Oncology, 2021
Colorectal cancer is one of the most common malignancies worldwide. Oxaliplatin is the first-line chemotherapeutic agent for the treatment of advanced colorectal cancer. However, acquired resistance to oxaliplatin limits its therapeutic efficacy, and the
Xiao-Lan Qian, Fang Zhou, Song Xu, Jian Jiang, Zhi-Peng Chen, Shao-Kai Wang, Yun Zuo, Chen Ni   +7 more
doaj   +1 more source

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim, A Rennicke, AB Sandler, AP Jekunen, BA Jansen, BA Teicher, Britta K. Stordal, BS Burns, C Kollmannsberger, C Kollmannsberger, CR Culy, D Pectasides, D Pectasides, DC Marks, G Belvedere, G Lenz, G Tisman, GA Hospers, H Kawai, H Kuroda, HD Preisler, HD Preisler, IS Song, J Liu, JM Woynarowski, JM Woynarowski, K Suzukake, K Yamamoto, KV Grech, L Pendyala, L Poulain, M Abal, M Markman, M Mishima, Mary W. Davey, N Jain, N Savaraj, N Thatcher, O Rixe, P Chollet, P Soulie, PJ Kuppen, PR Twentyman, R Sockalingam, RD Christen, Ross A. Davey, S Hector, S Ohta, SG Chaney, SL Lai, SW Johnson, T Fojo, T Moritaka, T Tashiro, V Dieras, VL Locke, WS Hong, Z El Akawi, Z Wang   +58 more
core   +2 more sources

Alteration of chromatin high‐order conformation associated with oxaliplatin resistance acquisition in colorectal cancer cells

Exploration, 2023
Oxaliplatin is a first‐line chemotherapy drug widely adopted in colorectal cancer (CRC) treatment. However, a large proportion of patients tend to become resistant to oxaliplatin, causing chemotherapy to fail.
Peilong Li, Xueying Shang, Qinlian Jiao, Qi Mi, Mengqian Zhu, Yidan Ren, Juan Li, Li Li, Jin Liu, Chuanxin Wang, Yi Shi, Yunshan Wang, Lutao Du   +12 more
doaj   +1 more source